Health AI Central
Share:
Peer-Reviewed Publication
J Immunother Cancer2025;13(7)July 30, 2025Journal Article

Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade.

David N Ciccone1, Fu-Shan Kuo1, Scott Boiko1, Samantha Carreiro1, Neelu Kaila1, Joshua J McElwee1, Peter J Tummino1, Christine Loh2
1Nimbus Therapeutics Inc, Boston, Massachusetts, USA.
2Nimbus Therapeutics Inc, Boston, Massachusetts, USA christine.loh@nimbustx.com.
PubMed PMC DOI PDF

Abstract

BACKGROUND: HPK1 (hematopoietic progenitor kinase 1, MAP4K1), an MAP4K serine/threonine kinase family member, is a negative regulator of immune cell function. Genetic HPK1 kinase inactivation or knockout in mice leads to immune cell activation and tumor growth suppression, providing a strong rationale for targeting HPK1 kinase activity as an immuno-oncology therapy. METHODS: A structure-guided dr…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.